CD19 and neoplasm: Factors hindering the effectiveness of CAR T cell therapy include a high tumor burden prior to CAR T cell infusion 12,13, loss of or decreased CD19 expression on tumor cells 14,15, tumor genetic alterations 16,17, and the highly differentiated or dysfunctional state of CAR T cells 18,19.